Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
28-day Repeated-dose Study of SCO-240 in Healthy Adult Male Subjects
jRCTs031250659Phase 1Active, not recruiting
- Sponsor
- Japan Agency for Medical Research and Development
- Start
- Feb 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of SCO-240 in growth hormone deficiency (GHD) (2 arms), sponsored by Japan Agency for Medical Research and Development. Primary endpoints: Safety and tolerability of SCO-240 and Pharmacodynamic effects of SCO-240. Started Feb 2026; status: active, not recruiting.
02
Drugs
SCO-240
03
Conditions
growth hormone deficiency (GHD)
Beyond the preview
Go deeper on jRCTs031250659.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs031250659.